Johnson & Johnson is making the investment to help meet its 2030 target of launching 20 new medicines and expanding filings ...

Johnson & Johnson (JNJ) has discontinued a Phase 2 study of its drug TAR-200 for the treatment of muscle-invasive bladder ...

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Enhance your stock picks with dividend metrics like per-share dividends, yield, frequency, payout ratios, and more.

In this article, we are going to take a look at where Johnson & Johnson (NYSE:JNJ) stands against other cheap blue chip stocks. The technology sector has been the highlight of the stock market.

Below is Validea's guru fundamental report for JOHNSON & JOHNSON (JNJ). Of the 22 guru strategies we follow, JNJ rates highest using our P/B Growth Investor model based on the published strategy ...

Johnson & Johnson's stock has seen modest gains in recent months, supported by approvals for treatments like Tremfya, Darzalex Faspro, and Rybrevant. Despite positive developments, litigation ...

In this article, we will look at where Johnson & Johnson (NYSE:JNJ) ranks among the best stocks to buy according to billionaire Ray Dalio. Ray Dalio was born in 1949 and graduated from Long Island ...

Given its attractive valuation, we believe that Disney stock (NYSE: DIS) is currently a better pick than the pharmaceuticals bellwether – Johnson & Johnson stock (NYSE: JNJ). The decision to ...

Johnson & Johnson (JNJ) closed the most recent trading day at $166.99, moving +0.89% from the previous trading session. The stock's performance was ahead of the S&P 500's daily gain of 0.13%.

J&J ends Phase 2 study on antiviral mosnodenvir for dengue prevention in adults aged 18-65. Efficacy data from the discontinued study will be released after ongoing final analysis. On Friday ...